Thomas Penn - ANI Pharmaceuticals Director
| ANIP Stock | USD 66.30 0.58 0.87% |
Director
Mr. Thomas A. Penn is Independent Director of the Company. Mr. Penn is employed by MVP Management, of which he serves as Vice President. MVP Management conducts business as MVP Capital Partners. MVP Management is the investment management company for MVP II, of which Mr. Penn is a Partner. Mr. Penn has also served as a managing director at and owner of Penn Venture I LLC since 2007. Penn Venture I LLC owns fifty percent of Penn Venture Associates, LLC. Penn Venture Associates, LLC is the general partner of Penn Venture Partners, L.P., an investment fund focused on investments in central Pennsylvania. Previously, Mr. Penn served as chief executive officer of Tektagen, Inc. and a partner at Boston Millennia Partners. He also serves or has served as a director of several privatelyheld service, manufacturing, technology, life sciences and healthcare companies. These companies include Benten BioServices, Inc., Deltagen, Inc., NanoHorizons Inc., GCA Services, Inc., and Andrews International, Inc. Mr. Penn is a graduate of the Massachusetts Institute of Technology, the Stanford University Graduate School of Business, and the University of Pennsylvania Law School. since 2013.
| Age | 72 |
| Tenure | 11 years |
| Address | 210 Main Street West, Baudette, MN, United States, 56623 |
| Phone | 218 634 3500 |
| Web | https://www.anipharmaceuticals.com |
ANI Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0372 % which means that it generated a profit of $0.0372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0472 %, meaning that it created $0.0472 on every $100 dollars invested by stockholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/16/2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.07. At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 04/16/2024, Liabilities And Stockholders Equity is likely to grow to about 949.6 M, while Non Current Liabilities Other is likely to drop slightly above 14.4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gary Michael | PetIQ Inc | 77 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Scott Huff | PetIQ Inc | 46 | |
| Joseph Mollica | Neurocrine Biosciences | 59 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| Will Santana | PetIQ Inc | 45 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| Larry Bird | PetIQ Inc | 63 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| Corinne Nevinny | Neurocrine Biosciences | 57 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Susan Sholtis | PetIQ Inc | 51 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Mark First | PetIQ Inc | 53 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| Richard Pops | Neurocrine Biosciences | 56 | |
| Ronald Kennedy | PetIQ Inc | 71 | |
Management Performance
| Return On Equity | 0.0472 | ||||
| Return On Asset | 0.0372 |
ANI Pharmaceuticals Leadership Team
Elected by the shareholders, the ANI Pharmaceuticals' board of directors comprises two types of representatives: ANI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ANI. The board's role is to monitor ANI Pharmaceuticals' management team and ensure that shareholders' interests are well served. ANI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ANI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Nash, Independent Director | ||
| Elizabeth JD, Chief Disease | ||
| Charlotte Arnold, CFO, Vice President | ||
| Daniel Raynor, Director | ||
| Stephen Carey, CFO, Vice President | ||
| David Sullivan, VP of Quality Operations | ||
| Muthusamy RPh, COO RD | ||
| Nikhil Lalwani, CEO President | ||
| Thomas Haughey, Independent Director | ||
| Patrick Walsh, Independent Director | ||
| Chad Gassert, Senior Strategy | ||
| Ori Gutwerg, Senior Generics | ||
| Fred Holubow, Independent Director | ||
| Tracy Marshbanks, Director | ||
| Arthur Przybyl, CEO and President and Director | ||
| Thomas Penn, Director | ||
| Mary MD, Chief Officer | ||
| Robert Brown, Chairman of the Board | ||
| Mark Ginski, Vice President of Corticotropin Product Development | ||
| Robert Schrepfer, VP of New Bus. Devel. and Contract Manufacturing | ||
| Krista Davis, Senior Officer | ||
| Meredith Cook, General VP | ||
| Karen Quinn, Vice President - Corticotropin Regulatory Affairs | ||
| James Marken, Senior Development | ||
| Peter Lankau, Director | ||
| Christopher Mutz, Senior Disease |
ANI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ANI Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0472 | ||||
| Return On Asset | 0.0372 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.4 B | ||||
| Shares Outstanding | 20.98 M | ||||
| Shares Owned By Insiders | 11.20 % | ||||
| Shares Owned By Institutions | 75.45 % | ||||
| Number Of Shares Shorted | 197.03 K | ||||
| Price To Earning | 43.35 X |
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ANI Stock
| 0.93 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.79 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against ANI Stock
| 0.83 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
| 0.72 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.68 | NVS | Novartis AG ADR Earnings Call This Week | PairCorr |
| 0.59 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.44 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share 0.85 | Revenue Per Share 27.044 | Quarterly Revenue Growth 0.397 | Return On Assets 0.0372 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.